Abstract
Lymphodepleting preconditioning with high-dose chemotherapy is commonly used to increase the clinical efficacy of adoptive T cell therapy (ACT) strategies, however, with severe toxicity for patients. Conversely, oncolytic adenoviruses are safe and, when engineered to express interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α), they can achieve antitumor immunomodulatory effects similar to lymphodepletion. Therefore, we compare the safety and efficacy of such adenoviruses with a cyclophosphamide- and fludarabine-containing lymphodepleting regimen in the setting of ACT. Human adenovirus (Ad5/3-E2F-D24-hTNF-α-IRES-hIL-2; TILT-123) replication was studied using a Syrian hamster pancreatic tumor model (HapT1) infused with tumor-infiltrating lymphocytes (TILs). Using the oncolytic virus instead of lymphodepletion resulted in superior efficacy and survival. Immune cells responsive to TNF-α IL-2 were studied using an immunocompetent mouse melanoma model (B16.OVA) infused with ovalbumin-specific T (OT-I) cells. Here, the adenovirus approach improved tumor control together with increased intratumoral Th1 cytokine levels and infiltration of CD8+ T cells and CD86+ dendritic cells. Similar to humans, lymphodepleting preconditioning...Continue Reading
Citations
Mar 25, 2019·Expert Opinion on Biological Therapy·Victor Cervera-CarrasconAkseli Hemminki
Nov 30, 2019·Frontiers in Oncology·Mubalake AbudoureyimuXiaoyuan Chu
Aug 19, 2020·Cancer Control : Journal of the Moffitt Cancer Center·Ting-Miao WuDa Fu
Nov 9, 2019·Pharmaceutics·Alisa A ShaimardanovaValeriya V Solovyeva
Jul 1, 2020·Journal of Hematology & Oncology·Otto HemminkiAkseli Hemminki
May 28, 2020·Cancers·Mizuho Sato-DahlmanMasato Yamamoto
Sep 15, 2020·Oncoimmunology·Victor Cervera-CarrasconAkseli Hemminki
May 6, 2019·Nature Reviews. Cancer·Lindsey N Kent, Gustavo Leone
Nov 25, 2020·Expert Opinion on Drug Discovery·Shunchuan Zhang, Samuel D Rabkin
Jan 31, 2021·Cells·Riikka HavunenAkseli Hemminki
Feb 6, 2021·Cancers·María Florencia MercoglianoRoxana Schillaci
Dec 25, 2019·Current Opinion in Biotechnology·Erkko Ylösmäki, Vincenzo Cerullo
Apr 4, 2021·Cancers·Teresa KrabbeJennifer Altomonte
Apr 6, 2021·International Journal of Genomics·Lin-Lin TianSen-Tai Ding
May 1, 2021·Cells·Joao SantosAkseli Hemminki
May 26, 2021·Nature Immunology·Yugang GuoLi Tang
Aug 10, 2021·Frontiers in Microbiology·Yaqi ZhaoBin Xu